Biomaterial Database

Cyclophosphamide therapy in the management of nephrotic syndrome. 1974

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

UI	MeSH Term	Description	Entries
D007223	Infant	A child between 1 and 23 months of age.	Infants
D008297	Male		Males
D009404	Nephrotic Syndrome	A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction.	Childhood Idiopathic Nephrotic Syndrome,Frequently Relapsing Nephrotic Syndrome,Multi-Drug Resistant Nephrotic Syndrome,Pediatric Idiopathic Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndrome,Steroid-Resistant Nephrotic Syndrome,Steroid-Sensitive Nephrotic Syndrome,Multi Drug Resistant Nephrotic Syndrome,Nephrotic Syndrome, Steroid-Dependent,Nephrotic Syndrome, Steroid-Resistant,Nephrotic Syndrome, Steroid-Sensitive,Nephrotic Syndromes,Steroid Dependent Nephrotic Syndrome,Steroid Resistant Nephrotic Syndrome,Steroid Sensitive Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndromes,Steroid-Resistant Nephrotic Syndromes,Steroid-Sensitive Nephrotic Syndromes,Syndrome, Nephrotic,Syndrome, Steroid-Sensitive Nephrotic
D011241	Prednisone	A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.	Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D012008	Recurrence	The return of a sign, symptom, or disease after a remission.	Recrudescence,Relapse,Recrudescences,Recurrences,Relapses
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D002675	Child, Preschool	A child between the ages of 2 and 5.	Children, Preschool,Preschool Child,Preschool Children
D003520	Cyclophosphamide	Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.	(+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004351	Drug Resistance	Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.	Resistance, Drug
D004359	Drug Therapy, Combination	Therapy with two or more separate preparations given for a combined effect.	Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug

Related Publications

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

[Cyclophosphamide therapy of nephrotic syndrome in childhood].

January 1970, Archiv fur Kinderheilkunde,

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Cyclophosphamide therapy in the nephrotic syndrome in childhood.

March 1969, British medical journal,

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Cyclophosphamide pulse therapy in relapsing nephrotic syndrome.

January 1991, Nephron,

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Cyclophosphamide pulse therapy in frequently relapsing nephrotic syndrome.

January 1993, Nephron,

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Pulse cyclophosphamide therapy in frequently relapsing nephrotic syndrome.

October 2001, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Cyclophosphamide pulse therapy in frequently relapsing nephrotic syndrome.

January 1990, Nephron,

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Pulse cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

May 2004, Pediatric nephrology (Berlin, Germany),

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Cyclophosphamide therapy in idiopathic nephrotic syndrome--a new treatment.

May 1971, Journal of the Irish Medical Association,

R N Srivastava, and G Mayekar, and R Anand, and V P Choudhry, and O P Ghai

Cyclophosphamide therapy in adults with minimal-change nephrotic syndrome.

June 1972, Lancet (London, England),